MDCK-MRP2 - Dkfz

Forschungsschwerpunkt E
Innovative Krebsdiagnostik und -therapie
wiesen werden, dass Patientinnen mit Zervixkarzinomen
eine humorale Immunantwort gegen p16ink4a entwickeln,
die von diagnostischem und eventuell prognostischem Wert
für die Beurteilung von Patienten mit Präneoplasien sein
könnte (Linnebacher et al., Manuskript in Vorbereitung).
Entwicklung einer Antigen-spezifischen Vakzine
mit CTA1-DD Fusionsproteinen in einem Rattenmodell
der DMH-induzierten kolorektalen
Karzinogenese
CTA1-DD ist eine Kombination aus Teilen des Choleratoxins,
das starke adjuvante Eigenschaften hat, und des Proteins
A von S. aureus, das eine Ig-Bindungsdomäne besitzt. Das
Fusionsprotein wird gegenwärtig benutzt, um effiziente
Vakzinen gegen verschiedene mikrobielle Antigene zu entwickeln.
In dieser Studie untersuchen wir den Einsatz des
CTA1-DD Fusionsproteins als Adjuvanz für die Entwicklung
einer therapeutischen, antigen-spezifischen Kolonkarzinomvakzine.
Wir haben mehrere tumorspezifischen Antigene in einem
bekannten Ratten-Modellsystem von chemisch induzierten
Kolontumoren und der aus diesem Modell abgeleiteten
Zelllinie CC531 identifiziert [7, 19], unter diesen mutierte
Onkogene wie k-ras oder β-Catenin und tumorspezifisch
überexprimierte Gene wie cyclin E, p16ink4a, BNP, und
WT1, die auch als relevante Tumor-Antigene in menschlichen
Kolon- und anderen soliden Tumoren gefunden wurden
[52 21, 22]. Diese Modellantigene werden zur Zeit
auf ihre Fähigkeit untersucht, eine effiziente antitumorale
Immunantwort in Ratten zu erzeugen, zunächst in einem
therapeutischen und dann in einem präventiven Ansatz.
Publikationen
[1] Bonk, T. et al. Matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry-based detection of microsatellite
instabilities in coding DNA sequences: a novel approach
to identify DNA-mismatch repair-deficient cancer cells.
Clin.Chem. 49.4 (2003): 552-61.
[2] Bonk, T. et al. Molecular diagnosis of familial adenomatous
polyposis (FAP): genotyping of adenomatous polyposis coli (APC)
alleles by MALDI-TOF mass spectrometry. Clin.Biochem. 35.2
(2002): 87-92.
[3] Dihlmann, S., S. Klein, and M. von Knebel Doeberitz. Reduction
of beta-catenin/T-cell transcription factor signaling by aspirin
and indomethacin is caused by an increased stabilization of phosphorylated
beta-catenin. Mol.Cancer Ther. 2.6 (2003): 509-16.
[4] Dihlmann, S., A. Siermann, and Doeberitz M. von Knebel. The
nonsteroidal anti-inflammatory drugs aspirin and indomethacin
attenuate beta-catenin/TCF-4 signaling. Oncogene 20.5 (2001):
645-53.
[5] Foulkes, W. D. et al. The founder mutation MSH2*1906G->C
is an important cause of hereditary nonpolyposis colorectal cancer
in the Ashkenazi Jewish population. Am.J.Hum.Genet. 71.6
(2002): 1395-412.
[6] Gebert, J. et al. Molecular profiling of sporadic colorectal tumors
by microsatellite analysis. Int.J.Oncol. 16.1 (2000): 169-
79.
[7] Germann, A. et al. Expression profiling of CC531 colon carcinoma
cells reveals similar regulation of beta-catenin target genes
by both butyrate and aspirin. Int.J.Cancer 106.2 (2003): 187-
97.
[8] Grips, E. et al. [Glioblastoma multiforme as a manifestation of
Turcot syndrome]. Nervenarzt 73.2 (2002): 177-82.
[9] Gurrola-Diaz, C. et al. Reduced expression of the neuron restrictive
silencer factor permits transcription of glycine receptor
alpha1 subunit in small-cell lung cancer cells. Oncogene 22.36
(2003): 5636-45.
E110
Gentherapie von Tumoren
[10] Kalka, D. et al. The plasma membrane ganglioside sialidase
cofractionates with markers of lipid rafts.
Biochem.Biophys.Res.Commun. 283.4 (2001): 989-93.
[11] Keller, M. et al. Comprehensive genetic counseling for families
at risk for HNPCC: impact on distress and perceptions.
Genet.Test. 6.4 (2002): 291-302.
[12] Keller, M. et al. Acceptance of and attitude towards genetic
for HNPCC: a comparison of participants and non-participants in
genetic counselling. Dis.Colon Rectum 47 (2004): 153-62.
[13] Kienle, P. et al. Decreased detection rate of disseminated
tumor cells of rectal cancer patients after preoperative chemoradiation:
a first step towards a molecular surrogate marker for
neoadjuvant treatment in colorectal cancer. Ann.Surg. 238.3
(2003): 324-30.
[14] Kienle, P. et al. Detection of isolated disseminated tumor
cells in bone marrow and blood samples of patients with hepatocellular
carcinoma. Arch.Surg. 135.2 (2000): 213-18.
[15] Klaes, R. et al. p16INK4a immunohistochemistry improves
interobserver agreement in the diagnosis of cervical intraepithelial
neoplasia. Am.J.Surg.Pathol. 26.11 (2002): 1389-99.
[16] Klaes, R. et al. Overexpression of p16(INK4A) as a specific
marker for dysplastic and neoplastic epithelial cells of the cervix
uteri. Int.J.Cancer 92.2 (2001): 276-84.
[17] Koch, M. et al. Hematogenous tumor cell dissemination during
colonoscopy for colorectal cancer. Surg.Endosc. 18.4 (2004):
587-591.
[18] Koch, M. et al. Comparative analysis of tumor cell dissemination
in mesenteric, central, and peripheral venous blood in patients
with colorectal cancer. Arch.Surg. 136.1 (2001): 85-89.
[19] Koesters, R. et al. Predominant mutation of codon 41 of the
beta-catenin proto-oncogene in rat colon tumors induced by 1,2dimethylhydrazine
using a complete carcinogenic protocol. Carcinogenesis
22.11 (2001): 1885-90.
[20] Koesters, R. et al. WT1 is a tumor-associated antigen in colon
cancer that can be recognized by in vitro stimulated cytotoxic
T cells. Int.J.Cancer 109.3 (2004): 385-92.
[21] Koesters, R. et al. Nuclear accumulation of beta-catenin
protein in Wilms’ tumours. J.Pathol. 199.1 (2003): 68-76.
[22] Koesters, R. and Doeberitz M. von Knebel. The Wnt signaling
pathway in solid childhood tumors. Cancer Lett. 198.2
(2003): 123-38.
[23] Kopitz, J. et al. Homodimeric galectin-7 (p53-induced gene
1) is a negative growth regulator for human neuroblastoma cells.
Oncogene 22.40 (2003): 6277-88.
[24] Kopitz, J., C. Oehler, and M. Cantz. Desialylation of extracellular
GD1a-neoganglioprotein suggests cell surface orientation
of the plasma membrane-bound ganglioside sialidase activity in
human neuroblastoma cells. FEBS Lett. 491.3 (2001): 233-36.
[25] Lacroix, J. et al. Sensitive detection of rare cancer cells in
sputum and peripheral blood samples of patients with lung cancer
by preproGRP-specific RT-PCR. Int.J.Cancer 92.1 (2001): 1-8.
[26] Linnebacher, M. et al. Frameshift peptide-derived T-cell
epitopes: a source of novel tumor-specific antigens. Int.J.Cancer
93.1 (2001): 6-11.
[27] Luft, F. et al. Detection of integrated papillomavirus sequences
by ligation-mediated PCR (DIPS-PCR) and molecular
characterization in cervical cancer cells. Int.J.Cancer 92.1
(2001): 9-17.
[28] Oehler, C., J. Kopitz, and M. Cantz. Substrate specificity
and inhibitor studies of a membrane-bound ganglioside sialidase
isolated from human brain tissue. Biol.Chem. 383.11 (2002):
1735-42.
[29] Plaschke, J. et al. Eight novel MSH6 germline mutations in
patients with familial and nonfamilial colorectal cancer selected by
loss of protein expression in tumor tissue. Hum.Mutat. 23.3
(2004): 285.
DKFZ 2004: Wissenschaftlicher Ergebnisbericht 2002 - 2003
349